GERMANTOWN, Md. & HILDEN, Germany & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Tecan Group AG (SIX Swiss Exchange: TECN), a global leader in laboratory automation and liquid handling technology, announced today a collaboration to improve the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the utilization of Tecan’s Fluent® Laboratory Automation workstation for the aliquoting of samples for the optional Lithium Heparin single-tube workflow. The Fluent instruments will be supplied directly to laboratories through Tecan’s Life Sciences Business.
QIAGEN’s fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection based on world leading interferon gamma release assay (IGRA) technology.
QuantiFERON-TB Gold Plus offers customers the most flexible workflow among latent TB screening tests, including a single-tube option that enables efficient screening in large-scale programs by collecting blood samples at patient sites and transporting them to labs for processing up to 53 hours after venipuncture.
The two parties are working together to optimize a solution that standardizes and automates the manual steps in liquid handling for the aliquoting of samples. Customers will be able to leverage the high-performance Fluent automation system and thereby achieve the goal of significantly reducing hands-on time, providing greater ease of use and ensure consistency in pre-analytic methods and thereby reducing processing errors and variability between runs. Front-end automation solutions also offer laboratories efficient automation of single tube collection for QuantiFERON, and thereby create efficiency in the lab and improve the patient blood collection experience.
Please find the full press release here